Shedding of GD2 ganglioside by human neuroblastoma.
Substantial concentrations of the cell-surface glycosphingolipid, the disialoganglioside GD2, are uniformly present in human neuroblastoma tumors. This ganglioside can also be detected in the plasma of patients with neuroblastoma by direct thin-layer chromatographic analysis. Among 32 neuroblastoma patients in all clinical stages studied prior to the initiation of treatment, 27 (84%) showed measurably elevated plasma concentrations of GD2 (greater than or equal to 50 pmol/ml). The mean level (545 +/- 108 pmol/ml) was more than 50 times the normal plasma GD2 concentration of less than or equal to 10 pmol/ml. Circulating GD2 was not detected in the plasma of patients with the related, more differentiated tumors, ganglioneuroblastoma and ganglioneuroma, indicating an association of the shedding of this ganglioside with the undifferentiated phenotype. Circulating GD2 diminished in patients in response to therapy, and reappeared in patients whose disease recurred. The results suggest that the sequential determination of circulating GD2 will be of value in monitoring individual patients with neuroblastoma.
D000911:Antibodies, Monoclonal / Q000276:immunology; D016026:Bone Marrow Transplantation; D005732:Gangliosides / Q000097:blood* / Q000276:immunology; D006801:Humans; D009447:Neuroblastoma / Q000097:blood* / Q000175:diagnosis
D000911:Antibodies, Monoclonal; D005732:Gangliosides; C019403:ganglioside, GD2